Inozyme Pharma, Inc. (NASDAQ:INZY) Receives $17.00 Average Price Target from Analysts
Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) has been assigned a consensus rating of “Buy” from the eight ratings firms that are presently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have updated their coverage on the stock […]
More Stories
Eagle Point Credit Management Sells 6,816 Shares of ACRES Commercial Realty Corp. (NYSE:ACR) Stock
ACRES Commercial Realty Corp. (NYSE:ACR – Get Free Report) major shareholder Eagle Point Credit Management sold 6,816 shares of the...
Joseph A. Sprague Sells 2,325 Shares of Alaska Air Group, Inc. (NYSE:ALK) Stock
Alaska Air Group, Inc. (NYSE:ALK – Get Free Report) CEO Joseph A. Sprague sold 2,325 shares of the business’s stock...
Needham & Company LLC Boosts Duolingo (NASDAQ:DUOL) Price Target to $385.00
Duolingo (NASDAQ:DUOL – Get Free Report) had its price target upped by equities researchers at Needham & Company LLC from...
NorthWestern Energy Group (NYSE:NWE) Stock Rating Upgraded by Barclays
NorthWestern Energy Group (NYSE:NWE – Get Free Report) was upgraded by equities researchers at Barclays from an “underweight” rating to...
DA Davidson Initiates Coverage on MSA Safety (NYSE:MSA)
DA Davidson began coverage on shares of MSA Safety (NYSE:MSA – Get Free Report) in a research report issued to...
Oklo (NYSE:OKLO) Now Covered by Wedbush
Stock analysts at Wedbush initiated coverage on shares of Oklo (NYSE:OKLO – Get Free Report) in a report released on...